Vancomycin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种用于治疗多种细菌感染的抗生素，通过抑制适当的细胞壁合成来发挥作用。

An antibiotic used to treat a number of bacterial infections that acts by inhibiting proper cell wall synthesis.Bacterial Infection Approved(In Vitro):Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da. Vancomycin is a unique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode of action inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococci.(In Vivo):Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize infusion-related adverse effects. Subjects with normal creatinine clearance, vancomycin has an α-distribution phase of 30 min to 1 h and a β-elimination half-life of 6-12 h. The volume of distribution is 0.4–1 L/kg. The binding of vancomycin to protein ranges from 10% to 50%. Factors that affect the overall activity of vancomycin include its tissue distribution, inoculum size, and protein-binding effects. Vancomycin treatment of infected mice is associated with improved clinical, diarrhea, and histopathology scores and survival during treatment.

——

——

——

GPCR/G Protein

Antibacterial

Antibacterial

Infection

Bacterial Infection

1404-90-6

1449.254

C66H75Cl2N9O24

>98% (HPLC)

10 mM in DMSO

CC1C(C(CC(O1)OC2C(C(C(OC2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)C(C(C(=O)NC(C(=O)NC5C(=O)NC7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)C(NC(=O)C(C(C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)C(CC(C)C)NC)O)Cl)CO)O)O)(C)N)O

Vancomycin

(-20℃)

With Ice Pack

≥ 2 years